We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals
AMPH

135 hedge funds and large institutions have $458M invested in Amphastar Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 39 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 39

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

4% more capital invested

Capital invested by funds: $442M → $458M (+$15.8M)

1% more funds holding

Funds holding: 134 → 135 (+1)

0.3% less ownership

Funds ownership: 48.21% → 47.91% (-0.3%)

Holders
135
Holders Change
+1
Holders Change %
+0.75%
% of All Funds
2.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
58
Reduced
39
Closed
18
Calls
$221K
Puts
–
Net Calls
+$221K
Net Calls Change
+$221K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$3.81M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$3.37M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.95M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$2.63M
5
Goldman Sachs
Goldman Sachs
New York
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$5.51M
2
JP Morgan Chase
JP Morgan Chase
New York
-$2.81M
3
Millennium Management
Millennium Management
New York
-$2.69M
4
EI
EAM Investors
California
-$2.43M
5
BlackRock
BlackRock
New York
-$1.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
JA
151
JOYN Advisors
Georgia
– -$3K -137 Closed
3 4 5 6
7

AMPH Hedge Fund Activity: Q1 2019 in Review

135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2019, worth a combined $458M — up 3.6% from $442M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AMPH positions and 18 closed out — a net gain of 2 holders — while 58 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.81M. The largest seller was Invesco, cutting an estimated $5.51M.

  • 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2019, up from 134 in Q4 2018.
  • Funds reported $458M of Amphastar Pharmaceuticals stock for Q1 2019, up 3.6% quarter-over-quarter.
  • 20 funds opened new Amphastar Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of +2 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q1 2019 was Morgan Stanley, an estimated $3.81M added.
  • The largest Amphastar Pharmaceuticals seller in Q1 2019 was Invesco, an estimated $5.51M sold.

Based on aggregated 13F filings for Q1 2019.